Cite

HARVARD Citation

    Iede, K. et al. (2022). Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer. Pancreas. 51 (3), pp. 278-281. [Online]. 
  
Back to record